Vandana Singh on Muck Rack

Vandana Singh

Verified
Kolkata
As seen in: Benzinga, Medium, MSN, MSN Italy, MSN Singapore, Markets Insider, MSN España, Wiley Online Library, Yahoo News, Yahoo News UK, Yahoo Singapore and
Working with Benzinga as news editor for the healthcare sector www.benzinga.com/author/vandana-singh
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vandana

Contact Vandana, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus - Bausch & Lomb (NYSE:BLCO)

|
By Vandana Singh Verified
| Benzinga
Bausch + Lomb Corporation (NYSE:BLCO) on Thursday said it will discontinue development of BL1107 as a topical treatment for glaucoma after the candidate failed to meet the primary endpoint in a Phase 2 clinical trial. Trial Misses Primary And Key Secondary Endpoints The randomized, double-masked, three-arm, parallel-group Phase 2 study enrolled 159 adults with primary open-angle glaucoma or ocular hypertension.
Open in Who Shared Issue with article?

What's Going on With Qiagen Stock Friday? - Qiagen (NYSE:QGEN)

|
By Vandana Singh Verified
| Benzinga
Private Equity Firms Circle Qiagen The report, citing people familiar with the matter, said the process could also attract additional private equity firms and strategic buyers. Some potential suitors have indicated they may consider offering at least $50 per share if they decide to pursue a deal, according to the report.
Open in Who Shared Issue with article?

ResMed Analyst Backs Portfolio Reset - ResMed (NYSE:RMD)

|
By Vandana Singh Verified
| Benzinga
The move reflects ResMed’s 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare. • ResMed stock is showing downward pressure. What should traders watch with RMD? The divestiture also strengthens ResMed’s ability to reallocate capital and resources toward innovation, operational scale, and long-term value creation across its connected, home-based care ecosystem.
Open in Who Shared Issue with article?
See all 33,410 licensed articles (33,419 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified